Industry Overview

European DNA vaccine market was valued at $289.2 million in 2025 and is projected to reach $446.0 million by 2035, growing at a CAGR of 4.5% during the forecast period (2026–2035). The market is growing due to sustained investment in genetic vaccine research and the strengthening of plasmid DNA manufacturing capabilities across Europe. Increasing focus on oncology and emerging infectious diseases is driving demand for adaptable vaccine platforms that enable precise antigen design and rapid modification. In parallel, advancements in plasmid DNA delivery technologies, including electroporation and non-viral carrier systems, are improving cellular uptake efficiency and enhancing clinical feasibility in human applications. The region’s established biotechnology infrastructure and coordinated regulatory frameworks are further supporting translational research and cross-border clinical development.

Market Dynamics

Increasing Expansion of GMP Plasmid DNA Manufacturing Capacity Across Europe

The European DNA vaccine market is witnessing capacity expansion in GMP-grade plasmid DNA production, supporting both clinical and early-stage commercial supply requirements. Several contract development and manufacturing organizations are investing in dedicated plasmid suites to address rising demand from oncology and infectious disease programs. This localized manufacturing capability reduces dependency on external suppliers and shortens development timelines for European vaccine developers. Strengthened in-region production infrastructure also improves regulatory alignment and quality oversight.

Growing Focus on Veterinary DNA Vaccines to Address Livestock and Zoonotic Risks

The animal DNA vaccine segment in Europe is gaining momentum due to increasing emphasis on livestock disease prevention and zoonotic risk management. Veterinary applications benefit from structured regulatory pathways and strong demand for preventive immunization in high-value animal populations. DNA vaccine platforms offer stability and adaptability, which are advantageous for rapidly evolving infectious threats in agriculture. European animal health companies are expanding research programs to address productivity and biosecurity challenges. This growing veterinary focus is contributing to diversified revenue streams and strengthening the overall market structure for DNA vaccines in the region.

Market Segmentation

• Based on the type, the market is segmented into animal DNA vaccine, and human DNA vaccine.
• Based on the technology, the market is segmented into plasmid DNA vaccines technology, and plasmid DNA delivery technology.
• Based on the application, the market is segmented into oncology, infectious diseases, and others.

Human DNA Vaccine Segment Driven by Oncology Research Investment

The human DNA vaccine segment represents a leading sub-segment within the European DNA vaccine market, primarily driven by expanding oncology research programs. European biotechnology firms and academic consortia are prioritizing tumor-specific immunotherapy platforms that utilize plasmid DNA constructs for targeted antigen expression. This approach supports personalized cancer treatment strategies, aligning with the region’s strong clinical research infrastructure. In addition, collaborative funding mechanisms across European countries are accelerating early-stage trials in cancer indications. As oncology remains a high-priority therapeutic area, sustained R&D activity is reinforcing demand for human DNA vaccine technologies across the regional market.

Plasmid DNA Vaccines Technology Supported by Scalable Manufacturing

Plasmid DNA vaccine technology is a core technological sub-segment supporting growth in the European DNA vaccine market. Ongoing investments in GMP-grade plasmid production facilities are improving batch consistency and scalability for both human and animal applications. These manufacturing advancements reduce development bottlenecks and enhance supply chain reliability for clinical programs. European contract development and manufacturing organizations are expanding specialized plasmid production capabilities to meet rising demand. Consequently, strengthened production infrastructure is directly supporting commercialization readiness and long-term expansion of the DNA vaccine market in Europe.

Regional Outlook

European DNA Vaccine market is further divided by countries, including the UK, Germany, France, Italy, Spain, Russia, and the Rest of Europe.

Germany Leads European DNA Vaccine Market with Strong Biotech Base

Germany is the leading country in the European DNA vaccine market, underpinned by deep biotechnology expertise and advanced plasmid DNA manufacturing capabilities that support both clinical and commercial pathways. The country hosts major industry participants and vector production hubs, and its regulatory and funding environment facilitates collaborative research between academia and biotech firms on genetic vaccine platforms. Recent investments in GMP-grade plasmid DNA facilities and a robust ecosystem of CDMOs and pharmaceutical partners strengthen Germany’s position as a regional manufacturing hub. Local firms contribute to infectious disease and oncology DNA vaccine research while ensuring supply chain resilience within Europe’s broader market framework. As a result, Germany’s integrated research and production base continues to drive regional growth and consolidates its leadership in the European DNA vaccine landscape.

Market Players Outlook

The major companies operating in the European DNA vaccine market include BioNTech SE, Charles River Laboratories International, Inc., Lonza Group Ltd., Merck KGaA (Life Science Division), and Thermo Fisher Scientific Inc., among others. Market players are leveraging partnerships, collaborations, mergers, and acquisition strategies for business expansion and innovative product development to maintain their market positioning.

Recent Developments

• In June 2025, BioNTech SE announced that it would acquire CureVac N.V. in an all-stock deal. CureVac, a clinical-stage biotech focused on mRNA-based medicines for oncology and infectious diseases, will join BioNTech.
• In February 2023, BioNTech completed construction of its first proprietary plasmid DNA manufacturing facility in Marburg, Germany. This facility will enable BioNTech to independently produce plasmid DNA, a key material for mRNA vaccines, therapies, and cell therapies, supporting cancer and infectious disease products.
• In September 2022, ArchiMed, a trans-Atlantic private equity healthcare firm, invested in PlasmidFactory, a German gene and cell therapy specialist based in Bielefeld. Founded in 2000, PlasmidFactory is a leading contract manufacturer of plasmid and minicircle DNA.

The Report Covers

• Market value data analysis of 2025 and forecast to 2035.
• Annualized market revenues ($ million) for each market segment.
• Country-wise analysis of major geographical regions.
• Key companies operating in the European DNA vaccine market. Based on the availability of data, information related to new products and relevant news is also available in the report.
• Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
• Analysis of market-entry and market expansion strategies.
• Competitive strategies by identifying ‘who-stands-where’ in the market.